These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 25439775)

  • 1. Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage.
    Bartoli CR; Restle DJ; Zhang DM; Acker MA; Atluri P
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):281-9. PubMed ID: 25439775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
    Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
    JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Models for Translational Investigations of Left Ventricular Assist Device-Associated von Willebrand Factor Degradation.
    Restle DJ; Zhang DM; Hung G; Howard JL; Kallel F; Acker MA; Atluri P; Bartoli CR
    Artif Organs; 2015 Jul; 39(7):569-75. PubMed ID: 25810063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis.
    Bartoli CR; Zhang DM; Hennessy-Strahs S; Kang J; Restle DJ; Bermudez C; Atluri P; Acker MA
    Circ Heart Fail; 2018 Sep; 11(9):e004638. PubMed ID: 30354363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation.
    Kang J; Zhang DM; Restle DJ; Kallel F; Acker MA; Atluri P; Bartoli CR
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1747-1754.e1. PubMed ID: 26971377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System.
    Bartoli CR; Kang J; Zhang D; Howard J; Acker M; Atluri P; Motomura T
    Ann Thorac Surg; 2017 Apr; 103(4):1239-1244. PubMed ID: 27717422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic pathway(s) of acquired von willebrand syndrome with a continuous-flow ventricular assist device: in vitro findings.
    Dassanayaka S; Slaughter MS; Bartoli CR
    ASAIO J; 2013; 59(2):123-9. PubMed ID: 23438773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased RPM reduces von Willebrand factor degradation with the EVAHEART LVAS: implications for device-specific LVAD management.
    Bartoli CR; Kang J; Motomura T
    J Card Surg; 2020 Jul; 35(7):1477-1483. PubMed ID: 32652785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the mechanism(s) of von Willebrand factor degradation during mechanical circulatory support.
    Bartoli CR; Dassanayaka S; Brittian KR; Luckett A; Sithu S; Siess T; Raess DH; Spence PA; Koenig SC; Dowling RD; D'Souza SE
    J Thorac Cardiovasc Surg; 2014 May; 147(5):1634-43. PubMed ID: 24139617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.
    Rauch A; Legendre P; Christophe OD; Goudemand J; van Belle E; Vincentelli A; Denis CV; Susen S; Lenting PJ
    Thromb Haemost; 2014 Nov; 112(5):1014-23. PubMed ID: 25030452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices.
    Zayat R; Moza A; Grottke O; Grzanna T; Fechter T; Motomura T; Schmidt-Mewes C; Breuer T; Autschbach R; Rossaint R; Goetzenich A; Bleilevens C
    J Thorac Cardiovasc Surg; 2019 Feb; 157(2):591-599.e4. PubMed ID: 30414772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor disruption and continuous-flow circulatory devices.
    Proudfoot AG; Davidson SJ; Strueber M
    J Heart Lung Transplant; 2017 Nov; 36(11):1155-1163. PubMed ID: 28756118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shear-dependent platelet aggregation size.
    Chan CHH; Inoue M; Ki KK; Murashige T; Fraser JF; Simmonds MJ; Tansley GD; Watanabe N
    Artif Organs; 2020 Dec; 44(12):1286-1295. PubMed ID: 32735693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.
    Jilma-Stohlawetz P; Quehenberger P; Schima H; Stoiber M; Knöbl P; Steinlechner B; Felli A; Jilma B
    Thromb Res; 2016 Jan; 137():196-201. PubMed ID: 26616301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device.
    Meyer AL; Malehsa D; Budde U; Bara C; Haverich A; Strueber M
    JACC Heart Fail; 2014 Apr; 2(2):141-5. PubMed ID: 24720921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart.
    Reich HJ; Morgan J; Arabia F; Czer L; Moriguchi J; Ramzy D; Esmailian F; Lam L; Dunhill J; Volod O
    J Thromb Haemost; 2017 Aug; 15(8):1620-1624. PubMed ID: 28586149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new spin on acquired von Willebrand factor deficiency during continuous-flow left ventricular assist device support.
    Toole JM
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):289-90. PubMed ID: 25312230
    [No Abstract]   [Full Text] [Related]  

  • 18. Stress and Exposure Time on von Willebrand Factor Degradation.
    Jhun CS; Siedlecki C; Xu L; Lukic B; Newswanger R; Yeager E; Reibson J; Cysyk J; Weiss W; Rosenberg G
    Artif Organs; 2019 Feb; 43(2):199-206. PubMed ID: 30374981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of Von Willebrand Factor Cleavage by adamts-13 in Patients Supported by Left Ventricular Assist Devices.
    Zhou Y; Qin S; Hilton T; Tang L; Cruz M; Hernandez R; Moake JL; Tian Q; Frazier OH; Dong JF; Nascimbene A
    ASAIO J; 2017; 63(6):849-853. PubMed ID: 28682993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and In Vitro Evidence That Subclinical Hemolysis Contributes to LVAD Thrombosis.
    Bartoli CR; Zhang D; Kang J; Hennessy-Strahs S; Restle D; Howard J; Redline G; Bermudez C; Atluri P; Acker MA
    Ann Thorac Surg; 2018 Mar; 105(3):807-814. PubMed ID: 28942075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.